SULM – Schweizerische Union für Labormedizin | Union Suisse de Médecine de Laboratoire | Swiss Union of Laboratory Medicine

Sie sind hier | Vous êtes ici:

S. Podolar, G. Juricic, M. Sucic

1Institute of Clinical Chemistry, Clinical Hospital "Merkur", 2General Hospital Pula, 3Department of Cytology of Clinical Institute of Laboratory Diagnosis, Clinical Hospital Center Zagreb

Objective of this work was to: a) analyze granulocyte AP in peripheral blood in chronic myeloid leukemia (CML) patients treated with Glivec (CMLGl) and in control group of non-hematological patients (CGnH), and b) to compare microscopic and computer evaluation of granulocyte AP. Patients and methods. Granulocyte AP was evaluated in 20 CMLGl and 18 CGnH patients after cytochemical analysis for AP (1). Results. Microscopic and computer digital image analysis of granulocyte AP showed good, but negative correlation (r= - 0.81). Whole CMLGl group of patients had statistically lower microscopic granulocyte AP (median 4, range 0-172) in comparison to the CGnH patients (median 33, range 7-85) (p < 0.05). However, microscopic granulocyte AP in subgroup of 12 CML patients with no leukocyte changes in peripheral blood was not statistically different in comparison to CGnH patients. Summary and Conclusion. Correlation of microscopic and computer granulocyte AP evaluation was high and negative because of opposite analysis approach in two methods. High AP activity with high cytoplasm density gave high microscopic AP score but low computer gray scale values. Similar microscopic granulocyte AP in a subgroup of 12 CMLGl patients without leukocyte changes in peripheral blood and in CGnH patients point out to normalization of granulocyte AP in CMLGl patients with response to Glivec therapy (2,3).


1. McKenzie SB. Laboratory methods in hematology. In: McKenzie SB, editor. Textbook of Hematology, Williams and Wilkins, Baltimore, 1996: 601-622.
2. Bainton DF. Abnormal neutrophils in acute myelogenous leukemia: identification of subpopulations based on analysis of azurophil and specific granules. Blood Cells 1975; 1: 191-199.
3. Chrobak L. Voglova J. Imatinib mesylate (STI571) – a new oral target therapy for chronic myelogenous leukemia (CML). Acta Medica (Hradec Kralove). 2003; 46 (3): 85-9.


07. & 08.03.2019: Swiss eHealth Forum - Digitales Gesundheitswesen – Hope and > mehr


pipette 06/2018: Die Analyse der Darmflora | Analyse du microbiote

Aktuelle Ausgabe als E-Paper lesen


17.12.2018: Cheflaboranten/in 80%, (HFR) Tafers